David Lebovitz
Stock Analyst at Citigroup
(0.37)
# 1964
Out of 5,240 analysts
123
Total ratings
72.73%
Success rate
4.91%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Crinetics Pharmaceut... | Maintains: Strong Buy | 70 74 | 37.06 | 99.68% | 2 | Nov 14, 2024 | |
Biomarin Pharmaceuti... | Maintains: Neutral | 93 81 | 63.73 | 27.1% | 2 | Oct 30, 2024 | |
Madrigal Pharmaceuti... | Maintains: Buy | 382 371 | 274.4 | 35.2% | 3 | Aug 8, 2024 | |
Alnylam Pharmaceutic... | Maintains: Strong Buy | 291 342 | 250.03 | 36.78% | 30 | Aug 2, 2024 | |
Mirum Pharmaceutical... | Maintains: Strong Buy | 37 38 | 44.7 | -14.99% | 1 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Sell | 29 17 | 43.22 | -60.67% | 5 | Oct 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 111 92 | 105.91 | -13.13% | 6 | Feb 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 54 | 54.37 | -0.68% | 5 | Aug 4, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 408 372 | n/a | n/a | 5 | May 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 11 10 | n/a | n/a | 5 | May 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 38 35 | 33.49 | 4.51% | 6 | May 6, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 16 17 | 3.05 | 457.38% | 11 | Apr 30, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 11 | 3.77 | 191.78% | 7 | Feb 22, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 193 220 | n/a | n/a | 5 | Feb 4, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 50 500 | n/a | n/a | 2 | Dec 7, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 44 | n/a | n/a | 10 | Nov 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 194 199 | 135 | 47.41% | 11 | Nov 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 34 32 | 0.65 | 4823.08% | 2 | Nov 3, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 27 26 | n/a | n/a | 2 | Aug 13, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 119 129 | n/a | n/a | 3 | Mar 6, 2018 |